First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

BACKGROUND: Osimertinib became the standard treatment for patients with untreated EGFR-mutant advanced non-small cell lung cancer (aNSCLC) following results reported in the phase III randomized FLAURA trial. Because of strict exclusion criteria, patient populations included in pivotal trials are onl...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenzi, Martina, Ferro, Alessandra, Cecere, Fabiana, Scattolin, Daniela, Del Conte, Alessandro, Follador, Alessandro, Pilotto, Sara, Polo, Valentina, Santarpia, Mariacarmela, Chiari, Rita, Pavan, Alberto, Dal Maso, Alessandro, Da Ros, Valentina, Targato, Giada, Vari, Sabrina, Indraccolo, Stefano, Calabrese, Fiorella, Frega, Stefano, Bonanno, Laura, Conte, Pier Franco, Guarneri, Valentina, Pasello, Giulia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714585/
https://www.ncbi.nlm.nih.gov/pubmed/35641222
http://dx.doi.org/10.1002/onco.13951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714585/
https://www.ncbi.nlm.nih.gov/pubmed/35641222
http://dx.doi.org/10.1002/onco.13951

Ejemplares similares